Search Results

A U.S. federal court upheld a prior ruling in favor of Roche’s Genentech, finding that its blockbuster hemophilia treatment Hemlibra did not infringe on patent protections held by Takeda’s Baxalta.

As part of the Sublicense Agreement, Baxalta agreed to pay Xenetic a one-time payment of $7.5 million and single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.

SERB Pharmaceuticals has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective 3 June 2024.

Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar’s agreement with Baxalta Incorporated, a Takeda company, and MOVANTIK, under Nektar’s agreement with AstraZeneca AB. Under the terms of th

Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced the appointment of Brian Goff to its board of directors.

The FDA on Tuesday extended the label for Takeda’s immune globulin infusion as a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy.

Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced the appointments of Mary J. Janatpour, PhD, as Chief Scientific Officer and Shouryadeep “Deep” Srivastava, MD, PhD, as Senior Vice President of Clinical Development.